Mark Yates Selected Research

O,O'- dimethyl- O- (6- chlorobicyclo(3.2.0)heptadiene- 1,5- yl)phosphate

9/2019	Impact of the Dementia Care in Hospitals Program on acute hospital staff satisfaction.
1/2018	Evaluating the Impact of the Dementia Care in Hospitals Program (DCHP) on Hospital-Acquired Complications: Study Protocol.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Yates Research Topics

Disease

5	COVID-19 07/2022 - 01/2020
5	Rheumatoid Arthritis 10/2021 - 10/2019
4	Infections 10/2021 - 10/2016
3	Dementia (Dementias) 09/2019 - 02/2017
2	Neoplasms (Cancer) 07/2022 - 01/2020
2	Hypertension (High Blood Pressure) 01/2022 - 01/2020
2	Arthritis (Polyarthritis) 01/2022 - 01/2019
2	Rheumatic Diseases (Rheumatism) 10/2019 - 01/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 07/2022
1	Melanoma (Melanoma, Malignant) 07/2022
1	Necrosis 07/2022
1	Skin Neoplasms (Skin Cancer) 07/2022
1	Stroke (Strokes) 07/2022
1	Obesity 01/2022
1	Fatigue 01/2022
1	Pain (Aches) 01/2022
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2021
1	Pulmonary Embolism 01/2021
1	Venous Thromboembolism 01/2021
1	Herpes Zoster 01/2021
1	Diabetes Mellitus 01/2020
1	Gout 01/2020
1	Lung Diseases (Lung Disease) 01/2020
1	Cognitive Dysfunction 09/2019
1	Disease Susceptibility (Diathesis) 10/2016
1	Autoimmune Diseases (Autoimmune Disease) 10/2016

Drug/Important Bio-Agent (IBA)

3	Janus Kinase InhibitorsIBA 07/2022 - 01/2021
3	Tumor Necrosis Factor InhibitorsIBA 10/2021 - 01/2020
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2020
2	Interleukin-6 InhibitorsIBA 07/2022 - 01/2021
2	Immunomodulating AgentsIBA 10/2021 - 01/2021
2	Methotrexate (Mexate)FDA LinkGeneric 01/2021 - 01/2020
2	O,O'- dimethyl- O- (6- chlorobicyclo(3.2.0)heptadiene- 1,5- yl)phosphateIBA 09/2019 - 01/2018
1	Rituximab (Mabthera)FDA Link 07/2022
1	GlucocorticoidsIBA 07/2022
1	InterleukinsIBA 07/2022
1	Interleukin-12 (IL 12)IBA 07/2022
1	Prostaglandins AIBA 01/2022
1	remdesivirIBA 01/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2021
1	Biological ProductsIBA 10/2021
1	LipidsIBA 01/2021
1	EnzymesIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	upadacitinibIBA 01/2021
1	sarilumabIBA 01/2021
1	GLPG0634IBA 01/2021
1	tocilizumab (atlizumab)FDA Link 01/2021
1	Oxygen (Dioxygen)IBA 01/2020
1	CreatinineIBA 01/2020
1	AlbuminsIBA 01/2020
1	Janus KinasesIBA 01/2019
1	tofacitinibIBA 01/2019
1	CytokinesIBA 01/2019
1	baricitinibIBA 01/2019
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2016
1	IntegrinsIBA 10/2016
1	Proteins (Proteins, Gene)FDA Link 10/2016

Therapy/Procedure

5	Therapeutics 07/2022 - 01/2020
1	Self Care (Care, Self) 01/2022
1	Critical Care (Surgical Intensive Care) 01/2020
1	Polypharmacy 10/2019
1	Occupational Therapy (Therapy, Occupational) 02/2017